Preventive effects of rosuvastatin combined with venous hydration on contrast-induced nephropathy in patients with coronary heart diseases undergoing intervention therapy

AIM:To study the preventive effects of rosuvastatin combined with venous hydration on contrast-induced nephropathy in patients with acute coronary syndromes undergoing intervention therapy. METHODS: Two hundred and ten patients were randomly divided into two groups: intensive treatment group (108 patients) in which rosuvastain 20 mg/day was administrated before and 1 week after intervention combined with venous hydration 6 h before and after intervention and control group (102 patients) in which only rosuvastain 20 mg/day was administrated before and after intervention. Serum level of creatinine and creatinine clearance rate, incidence of contrast-induced nephropathy and serum level of hsCRP were observed. RESULTS: One day after intervention, serum level of creatinine increased in both intensive group and control group (P<0.05), but 2 days after intervention the serum level of creatinine in the intensive group decreased compared with that in control group and was equal to the level before intervention. One week after the intervention, the serum level of creatinine decreased to the level before intervention in both intensive group and control group. After intervention, creatinine clearance rate decreased in both intensive group and control group. The creatinine clearance rate in intensive group increased to the level before intervention 2 days after intervention; whereas the rate in the control group was still markedly lower than the level before intervention. The creatinine clearance rate in the control group increased to the level before intervention 1 week after the intervention. The incidence of contrast-induced nephropathy in the intensive group was 5.6% (six patients), whereas the incidence in the control group was 12.7% (13 patients). Serum hsCRP levels increased significantly in both intensive group and control group 1 day after intervention, but from 2 days to 1 week after intervention the serum level of hsCRP decreased significantly compared with that in control group (P<0.05). CONCLUSION: Intensive treatment of rosuvastatin combined with venous sodium chloride hydration markedly decreases the incidence of contrast-induced nephropathy in patients with acute coronary syndrome undergoing intervention therapy.